ArticleCEN case reports2025
Successful kidney transplantation using eltrombopag in a patient with MYH9-related disease.
Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thrombopoietin receptor agonists in inherited thrombocytopenias: an evolving mosaic of evidence.Research and practice in thrombosis and haemostasis · 2026Article
- [The application of thrombopoietin receptor agonists in the treatment of non-muscle myosin heavy chain 9-related disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MYH9-related disease is an autosomal dominant genetic disease characterized by congenital macrothrombocytopenia, sensorineural hearing loss, and progressive kidney failure. Severe cases require kidney replacement therapy in the patient's second decade of life, and thrombocytopenia constitutes a major risk factor for hemorrhagic complications during dialysis initiation or kidney transplantation. Serious bleeding complications have been reported to occur in the perioperative period despite adequate platelet transfusions. Additionally, platelet transfusion may induce the production of anti-platelet antibodies and donor-specific anti-human leukocyte antigen antibodies. We report a case of a 19-year-old woman with MYH9-related disease due to an R702C missense variant in the motor domain of the MYH9 gene who used prophylactic eltrombopag, a thrombopoietin receptor agonist, from 6 weeks before kidney transplantation. Before transplantation, her platelet count increased from 10 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.